Topotecan as single agent or in combination with carboplatin in pretreated and heavily pretreated patients with advanced ovarian cancer

被引：0

作者：

Martoni, A ^{[1
]}

Pelusi, G ^{[1
]}

De Jaco, P ^{[1
]}

Taroni, B ^{[1
]}

Cacciari, N ^{[1
]}

Angelelli, B ^{[1
]}

Marino, A ^{[1
]}

Zamagni, C ^{[1
]}

机构：

[1] S Orsola Malpighi Hosp, Div Med Oncol, Bologna, Italy

来源：

7TH BIENNIAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY | 1999年

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We studied the tolerability and the activity of topotecan as single agent in 19 consecutive patients with advanced ovarian cancer, pretreated with at least one platinum-based chemotherapy. We also investigated topotecan in combination with carboplatin in 7 consecutive patients with the same characteristics. No grade 3-4 nonhematologic toxicities were observed. Grade 3 and 4 neutropenia and thrombocytopenia were the most relevant side-effects, both in patients treated with topotecan alone and in patients treated with topotecan and carboplatin. An objective remission was documented in 27% of patients treated with topotecan and in 43% of patients treated with the combination regimen. Our experience confirms that topotecan is an active agent in pretreated advanced ovarian cancer patients, the limiting toxicity being represented by myelotoxicity.

引用

页码：253 / 256

页数：4

共 50 条

[21] Carboplatin and VP 16 in the treament of heavily pretreated breast cancer patients
Palmisano, V
Leonardi, V
Pepe, A
Savio, G
Laudani, A
Calabria, C
Blasi, L
Rondello, G
Agostara, B
ANNALS OF ONCOLOGY, 2005, 16 : 276 - 277
[22] Eribulin and carboplatin in heavily pretreated patients with metastatic breast cancer: A single institution experience.
Romano, Patricia Martin
Baraibar, Iosune
Fernandez-Hidalgo, Oscar
Santisteban, Marta
Espinos, Jaime
Salas, Diego
Sala, Pablo
Gardeazabal, Itziar
Zubiri Oteiza, Leyre
Aramendia, Jose M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
[23] Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer.
Gennatas, C
Mouratidou, D
Tsavaris, N
Andreadis, C
Michalaki, V
Psychogios, J
Poulakaki, N
Gennatas, S
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 63S - 63S
[24] TRABECTEDIN AS SINGLE-AGENT IN HEAVILY PRETREATED PATIENTS WITH RELAPSED OVARIAN CANCER (ROC): RESULTS FROM A RETROSPECTIVE STUDY
Salutari, V.
Ferrandina, G.
Vincenzi, B.
Marinaccio, M.
Naglieri, E.
Loizzi, V.
Carpano, S.
Lorusso, D.
Masciullo, V.
Scarciglia, M. L.
Amadio, G.
Tonini, G.
Scambia, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
[25] CARBOPLATIN IN PATIENTS WITH ADVANCED COLORECTAL-CANCER PRETREATED WITH FLUOROPYRIMIDINES
NOLE, F
BIGANZOLI, L
BUZZONI, R
BAJETTA, E
EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) : 1330 - 1331
[26] Salvage treatment with single-agent capecitabine (C) in patients (pts) with heavily pretreated advanced colorectal cancer (ACRC)
Ioannidis, GN
Ardavanis, AS
Orphanos, GS
Rigatos, GA
ANNALS OF ONCOLOGY, 2005, 16 : 286 - 286
[27] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Chura, Justin C.
Van Iseghem, Kelin
Downs, Levi S., Jr.
Carson, Linda F.
Judson, Patricia L.
GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
[28] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
Gorumlu, G.
Kucukzeybek, Y.
Kemal-Gul, M.
Karaca, B.
Cosan-Terek, M.
Karabulut, B.
Sanli, U. A.
Akman, L.
Ozsaran, A.
Dikmen, Y.
Uslu, R.
JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
[29] THE EFFECT OF SINGLE WEEKLY PACLITAXEL IN HEAVILY PRETREATED OVARIAN CANCER PATIENTS AND ITS ANTIANGIOGENIC EFFECTS
Kikuchi, Yoshihiro
Kita, Tsunekazu
Takano, Masashi
Kudoh, Kazuya
Saito, Keiko
Fujii, Kazuyuki
Sasaki, Naoki
ANTICANCER RESEARCH, 2004, 24 (5D) : 3535 - 3535
[30] VINORELBINE AS SINGLE-AGENT IN PRETREATED PATIENTS WITH ADVANCED BREAST-CANCER
BARNI, S
ARDIZZOIA, A
BERNARDO, G
VILLA, S
STRADA, MR
CAZZANIGA, M
ARCHILI, C
FRONTINI, L
TUMORI, 1994, 80 (04) : 280 - 282

← 1 2 3 4 5 →